Breast cancer trial seeks better tolerated treatment schedule
NCT ID NCT02630693
Summary
This study compared two different dosing schedules for the drug palbociclib when combined with standard hormone therapy for advanced breast cancer. Researchers wanted to see if a lower daily dose (100 mg every day) would work as well or better than the standard schedule (125 mg for 21 days, then 7 days off) while causing fewer side effects that require treatment breaks. The trial involved 180 women whose breast cancer had progressed despite previous hormone therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1, Canada
-
BCCA - Abbotsford Centre
Abbotsford, British Columbia, V2S 0C2, Canada
-
BCCA - Fraser Valley Cancer Centre
Surrey, British Columbia, V3V 1Z2, Canada
-
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6, Canada
-
CHA-Hopital Du St-Sacrement
Québec, Quebec, G1S 4L8, Canada
-
CHUM - Hopital Notre-Dame
Montreal, Quebec, H2L 4M1, Canada
-
Cancer Centre of Southeastern Ontario at Kingston
Kingston, Ontario, K7L 5P9, Canada
-
Centre hospitalier universitaire de Sherbrooke
Sherbrooke, Quebec, J1H 5N4, Canada
-
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
-
Dr. H. Bliss Murphy Cancer Centre
St. John's, Newfoundland and Labrador, A1B 3V6, Canada
-
Hopital du Sacre-Coeur de Montreal
Montreal, Quebec, H4J 1C5, Canada
-
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, L8V 5C2, Canada
-
Lakeridge Health Oshawa
Oshawa, Ontario, L1G 2B9, Canada
-
Niagara Health System
St. Catharines, Ontario, L2S 0A9, Canada
-
Ottawa Hospital Research Institute
Ottawa, Ontario, K1H 8L6, Canada
-
QEII Health Sciences Centre
Halifax, Nova Scotia, B3H 1V7, Canada
-
Royal Victoria Regional Health Centre
Barrie, Ontario, L4M 6M2, Canada
-
Stronach Regional Health Centre at Southlake
Newmarket, Ontario, L3Y 2P9, Canada
-
The Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
The Moncton Hospital
Moncton, New Brunswick, E1C 6Z8, Canada
-
University Health Network
Toronto, Ontario, M5G 2M9, Canada
-
Windsor Regional Cancer Centre
Windsor, Ontario, N8W 2X3, Canada
Conditions
Explore the condition pages connected to this study.